NICE recommends lung cancer treatment

Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published by NICE recommending osimertinib (also called Tagrisso and made by AstraZeneca) at two different places in the treatment pathway for locally advanced or metastatic epidermal growth factor receptor (EGFR)-positive NSCLC.
Source: NHS Networks - Category: UK Health Source Type: news